Physician profile
Thomas C Hammond
NPI 1629019799
$10,585.08
in general payments reported to CMS, 2019-2025
65 companies · $2,266 in 2025
The $2,266 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,334 · 2020: $818 · 2021: $1,017 · 2022: $484 · 2023: $1,609 · 2024: $2,057 · 2025: $2,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,731 · Education: $176 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,731.20 |
| Education | $176.13 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $869.80 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $856.92 | 2019-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $605.65 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Acorda Therapeutics, INC | $583.70 | 2019-2024 | Inbrija, Ampyra |
| Otsuka America Pharmaceutical, INC. | $566.00 | 2023-2025 | Rexulti, Nuedexta |
| Lilly USA, LLC | $553.62 | 2019-2025 | Amyvid, Kisunla |
| Emd Serono, INC. | $479.32 | 2019-2024 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $460.62 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Ucb, INC. | $437.78 | 2019-2025 | Briviact, Zilbrysq, Rystiggo |
| Mdd US Operations, LLC | $371.19 | 2019-2025 | Apokyn, Apokyn |
| Lundbeck LLC | $333.64 | 2019-2025 | Vyepti, Rexulti |
| Eisai INC. | $326.07 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $324.24 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $309.12 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $277.80 | 2019-2025 | Ultomiris |
Show all 64 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hammond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.